Thread by @nabarund

It's been 10 years since #OxyContin was re-engineered to make it hard to crush. But #publichealth benefits are still unclear. Here is a brief video of the epidemiology challenges.

vimeo.com/456967594

As guest speaker at FDA Advisory Committee

#RxEpi
#pharmacoepidemiology

A *product-centric* worldview, holds that abuse deterrence is primarily the property of the drug, and that that is the PRIMARY thing that changed with the reformulation, especially in the immediate aftermath.

A *person-centric* view holds that abuse deterrence is not merely a property of the drug, but rather an interaction between engineering and society, between physiochemical properties and point-of-prescribing medical decisions.

We must consider if abuse deterrence is inherent property of the drug itself, or if its intended effect lies in an interaction w/social context. If we accept it is more than a biochemical property, label language becomes more challenging, albeit w/potential to be more accurate.

Quote above from my comment on the Australian studies of OxyContin
thelancet.com/journals/lanps…

You can watch the conclusion of the Ad Com this afternoon
collaboration.fda.gov/dsarmaadpacsep…

Slides and 1000+ pages of scientific review from FDA and Purdue are here:
fda.gov/advisory-commi…

Props to our illustrator @brittainpeck

Interactive map on ADF prescribing here by @chris_delcher @_GYOh_ @yanningwang & others at @UK_COP

pharmacy.uky.edu/research-0/res…

Full paper here pubmed.ncbi.nlm.nih.gov/32686223/

Apologies for leaving @JohnRxBrown off the credits list! Didn’t realize you were on Tw. John conducted the analyses and surveys I presented along with Trish Freeman @UK_COP.